CONFIDENCE: A Multinational, Multicenter, Randomized, Parallel Group, Open-Label Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With Subcutaneous Injections of Copaxone(R) (Glatiramer Acetate) 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily
CONFIDENCE: A Multinational, Multicenter, Randomized, Parallel Group, Open-Label Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With Subcutaneous Injections of Copaxone(R) (Glatiramer Acetate) 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily
The primary objective of this study is to compare patient medication satisfaction as measured by the Medication Satisfaction Questionnaire (MSQ) scores between the Copaxone 40 mg/mL three time a week (TIW) group and the Copaxone 20 mg/mL once daily (QD) group over 6 months of treatment.
Inclusion Criteria:
Exclusion Criteria
Patient had any contraindication to Copaxone therapy.
Previous use of Copaxone 40 mg/mL three times per week.
Patients with progressive forms of MS.
Patients with neuromyelitis optica.
Use of experimental or investigational drugs, and/or participation in drug clinical studies within the 6 months prior to screening.
Patients who have been treated with; immunosuppressive medications, immunoglobulins and/or monoclonal antibodies, alemtuzumab, cladribine, cyclophosphamide or mitoxantrone at any time
Chronic (more than 30 consecutive days) systemic (IV, PO or IM) corticosteroid treatment within 6 months prior to screening visit.
Pregnancy or breastfeeding.
Clinically significant or unstable medical or surgical condition that would preclude safe and complete study participation
Employees of the clinical study site or any other individuals involved with the conduct of the study, or immediate family members of such individuals
DF, 03310, Mexico